Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARB-1467 (Arbutus Biopharma Corporation)
- Development stage
- Discontinued
- Lead developer
- Arbutus Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**ARB-1467** is an intravenously administered lipid nanoparticle RNA interference therapeutic originally developed as TKM-HBV for chronic hepatitis B. It contains three synthetic double-stranded small interfering RNA triggers directed at three conserved sites in the hepatitis B virus genome, designed to silence all four HBV transcripts and thereby reduce viral protein production, including hepatitis B surface antigen, and inhibit viral replication. Tekmira renamed the candidate ARB-1467 after its successor organization became Arbutus Biopharma; the program reached Phase 2a but was subsequently discontinued. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1447028/000117184315006068/0001171843-15-006068.txt))
02
Targets
HBeAg (Hepatitis B e antigen)HBV RNA (Hepatitis B virus RNA)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on ARB-1467 (Arbutus Biopharma Corporation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARB-1467 (Arbutus Biopharma Corporation).